Biopharma firm Verastem Oncology Q2 net loss widens

Verastem

07/08/2025 22:48

Overview

Verastem Q2 2025 net product revenue reaches $2.1 mln post AVMAPKI FAKZYNJA launch

Net loss for Q2 2025 widens to $25.9 mln, driven by increased expenses

Company ends Q2 2025 with $164.3 mln cash, runway into H2 2026

Result Drivers

AVMAPKI FAKZYNJA LAUNCH - Achieved $2.1 mln in net product revenue in first six weeks post-launch, following FDA approval for KRAS-mutated ovarian cancer treatment

INCREASED EXPENSES - Higher R&D and administrative costs linked to clinical advancements and product launch preparations

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$25.93 mln
Q2 Basic EPS
-$0.39
Q2 Income from Operations
-$43.76 mln
Q2 Operating Expenses
$45.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Verastem Inc is $14.00, about 59.1% above its August 6 closing price of $5.72

Press Release: ID:nBw6xZ8Vna

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)